What is the clinical evidence from this study?

Study design: Cohort. Population: Stable Coronary Artery Disease (n=205). Intervention: PF-4var/CXCL4L1 levels vs. Higher PF-4var levels. Primary outcome: Combined endpoint of cardiac death, non-fatal acute myocardial infarction, stroke or hospitalization for heart failure (HR 0.89, 95% CI 0.79-0.99, p=0.036).

February 23, 2012PLoS ONEOpen Access

PF-4var/CXCL4L1 Predicts Outcome in Stable Coronary Artery Disease Patients with Preserved Left Ventricular Function

Q: What does this research mean for the field?

Higher circulating PF-4var/CXCL4L1 levels are independently associated with a reduced risk of adverse cardiovascular events in patients with stable coronary artery disease and preserved left ventricular function. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

View Full Paper

Ask AI

Bookmark

Key result

Higher PF-4var/CXCL4L1 linked to ~11% lower risk of adverse cardiovascular events in stable CAD.

HR 0.89
95% CI 0.79-0.99
P=0.036
n=205

Why the study?

The role and prognostic value of the platelet-derived chemokine PF-4var/CXCL4L1 in stable coronary artery disease patients with preserved left ventricular function had not been studied.

Population

205 consecutive stable CAD patients with preserved LV function

Comparison

PF-4var, PF-4, and RANTES chemokine levels

Design

Prospective cohort study

Follow-up

Median 2.5 years

Authors

JSJohan De SutterPreventive Cardiology NVNico R. Van de VeireAZ Maria Middelares SSSofie StruyfRega Institute for Medical Research

Discussion

Member takes

Implication

Hypothesis-generating for PF-4var/CXCL4L1 in stable CAD prognosis; prospective validation required before clinical adoption.

Study Design

Type

Cohort (n=205)

Multicenter

Structured PICO

Population

205 patients with stable coronary artery disease and preserved left ventricular function, followed for a median of 2.5 years.

Outcome

Combined endpoint of cardiac death, non-fatal acute myocardial infarction, stroke or hospitalization for heart failure at median 2.5 years follow-upcomposite

Main Result

Hazard Ratio: 0.89 (95% CI 0.79–0.99)

p-value: p=0.036

Low levels of the platelet-derived chemokine PF-4var/CXCL4L1 independently predict adverse cardiovascular outcomes in patients with stable CAD and preserved LV function, providing prognostic value beyond NT-proBNP.

Limitations

Small sample size and low number of primary outcome events (n=20)
Single-center observational design
Lack of mechanistic evidence explaining the association between low PF-4var and CAD outcomes

Cite This Study

Sutter et al. (2012) conducted a cohort in Stable Coronary Artery Disease (n=205). PF-4var/CXCL4L1 levels vs. Higher PF-4var levels was evaluated on Combined endpoint of cardiac death, non-fatal acute myocardial infarction, stroke or hospitalization for heart failure (HR 0.89, 95% CI 0.79-0.99, p=0.036). Higher levels of PF-4var/CXCL4L1 were independently associated with a reduced risk of adverse cardiovascular events (HR 0.89) in patients with stable coronary artery disease.

synapsesocial.com/papers/6aaa50b4c0d26b63ae086482 https://doi.org/10.1371/journal.pone.0031343

Topics

Coronary artery disease

View Full Paper

Ask AI

Bookmark

PF-4var/CXCL4L1 Predicts Outcome in Stable Coronary Artery Disease Patients with Preserved Left Ventricular Function

Discussion

Member takes

Implication

Study Design

Structured PICO

Main Result

Limitations

Cite This Study

Topics

PF-4var/CXCL4L1 Predicts Outcome in Stable Coronary Artery Disease Patients with Preserved Left Ventricular Function

Discussion

Member takes

Implication

Study Design

Structured PICO

Main Result

Limitations

Cite This Study

Also Consider

Topics

Also Consider